OUR Founders
Vie Ventures’ founders come from the venture capital and biopharmaceutical industries with deep personal connections to autoimmune disease and philanthropy.
Steven St. Peter, MD and Luke Evnin, PhD worked together for a decade at MPM Capital, where they invested in three successive venture capital funds. Each brings a successful track record of life sciences investing and organizational leadership, and both are excited to have reunited at Vie Ventures.
Steven and Luke also have notable expertise in Immunology & Autoimmunity (I&A), including having supported disease-focused philanthropies to further their patient-centric missions. They are committed to leveraging these strengths and deep, personal networks with venture capital and public market investors to accelerate the development of innovative therapeutics.
Steven St. Peter, MD
Co-Founder & Managing Director
- Multiple successful investments and exits
- Founder and CEO of Aratana Therapeutics through IPO and commercialization
Venture capital: Two+ decades
Carlyle Group, Apax, MPM, 1315 Capital
Managing Director
2004-2012
Managing Director
2019-2025
The first and largest, type 1 diabetes-focused impact investing fund.
Luke Evnin, PhD
Co-Founder & Senior Advisor
- Created and built dozens of successful companies
- Co-recipient of Global Oncology Visionary Award
Venture capital: Three+ decades
Accel, MPM
Co-Founder & Managing
Director, 1997-2023
Senior Advisor, present
Chairman,
1999-Current
Largest funder of discovery research
and clinical development
OUR Team
Vie Ventures’ other team members share the founders’ passion for advancing new therapies to patients and have made a significant professional commitment to disease philanthropy.
Lou DeGennaro, PhD
Lou is the former CEO of the Leukemia and Lymphoma Society, and has been an advisor to Vie Ventures since fall 2024. Given the scientific and biological links between immuno-oncology and autoimmune disease, Lou’s involvement is particularly useful and relevant. Lou is primarily focused on implementing and managing Vie Ventures’ strategic collaborator relationships.
Shane Bates
Shane is a Founder and Partner at Bridge Alternatives, a leading alternative investment services platform. Supported by a team of professionals at Bridge Alternatives, Shane leads operations and serves as the CFO of Vie Ventures.
Steven Neier, PhD
Steven completed his graduate work in Immunology at the Mayo Clinic and helped launch and serves as a Principal with Dana-Farber Cancer Institute’s venture fund, Binney Street Capital. Steven also supported business development and venture philanthropy relationships within Dana-Farber’s Innovation Group. Steven is consulting with Vie’s investment team and helping to drive implementation of the investment strategy.
Jolyon Martin, PhD
Jolyon completed his graduate work in Immunology at the University of Cambridge, and his professional experience includes having founded and successfully exited a platform biotechnology company where he raised more than $50M in equity financing and closed commercial deals worth over $300M. Jolyon brings an international perspective, having been an advisor to the British Government on entrepreneurship and Jolyon is a member of the investment team and critical facilitator with Vie Ventures’ strategic collaborators.
Casey Hill
Casey is graduate of Concordia University in Montreal with experience in business development and marketing rooted in mission-driven organizations. Casey coordinates fundraising efforts that align capital with purpose thereby advancing Vie Ventures’ core mission.
